

**ONE-OF-A-KIND TOOL IN QUEBEC TO BE LAUNCHED
AT THE INSTITUT DE CARDIOLOGIE DE QUÉBEC, AT HÔPITAL LAVAL**

**MAJOR DONATION BY SERVIER CANADA TO THE ICQ WILL ENABLE THE
PROJECT'S IMPLEMENTATION**

Quebec – March 14, 2007 – The Institut universitaire de cardiologie et de pneumologie de l'Hôpital Laval will soon be acquiring a tool that is unique in Quebec, and that will allow a better assessment of the pertinence and efficacy of procedures performed on patients undergoing angioplasty.

A \$250,000 donation from the Servier Canada pharmaceutical company to the Institut de cardiologie de Québec will be used to create a major database that will include all of the 7,000 hemodynamic procedures performed annually, including some 2,800 coronary angioplasties. Among other things, this database will allow an analysis and comparison of the different methods currently used, and will ensure that the techniques are producing the expected outcomes. By carefully examining the various parameters in the database, the 13 cardiologists working in the hemodynamics laboratory can establish a complete portrait of each patient who undergoes a coronary angioplasty at Hôpital Laval.

“We must, at the local level, absolutely be able to better assess the operations that we perform. Each new technology we use has already undergone studies in other hospital centres in Canada or elsewhere. However, from a scientific viewpoint, we must determine whether the data obtained from other locations can also be applied locally,” said Dr. Robert De Larochellière, head of the hemodynamics division at Hôpital Laval.

The new database is scheduled to be implemented in September 2007. The parameters that will be available for analysis include all angioplasty procedures performed at Hôpital Laval.

The \$250,000 donation will cover the initial capital investment, including the purchase of additional computer equipment, as well as the acquisition and development of the database. Once the database is implemented, the funds will be used to pay for the services of a nurse and a secretary, who will be responsible for its update and for ensuring patient follow-up.

“This database will allow the Institut de cardiologie at Hôpital Laval to solidify its position as a leader in the treatment of coronary disease,” stated Dr. François Philippon, head of the multidisciplinary cardiology department at Hôpital Laval, and medical director of the Institut de cardiologie de Québec. “This new tool will help us realize our mission of excellence in ultra-specialized cardiovascular care for the three million citizens of central and eastern Quebec,” concluded Dr. Philippon.

- continued -

“Servier Canada is extremely proud to be associated with a project as significant as this database. Supporting the advancement of research is one of our company’s three fundamental goals. As such, the project being implemented at the Institut de cardiologie de Québec fits perfectly with our company’s values and our goal of improving the health of individuals,” indicated Mr. Michael Sumpter, Chief Executive Officer of Servier Canada.

Hemodynamics

Hemodynamics is a specialization that is used to diagnose blood flow problems and to act, as much as possible, to restore optimal blood circulation. This diagnostic procedure involves inserting a catheter into one or several arteries in order to visualize the presence of an obstruction or stenosis. At the therapeutic level, the hemodynamics specialist performs a balloon dilation at the site where arterial narrowing is observed, and inserts a coronary stent in order to improve blood circulation. This procedure is known as angioplasty.

About the Institut de cardiologie de Québec

The Institut de cardiologie de Québec was created in 1957. The goal of the organization is to provide financial support for cardiology research and teaching to researchers and to members of the multidisciplinary cardiology department at Hôpital Laval. The hospital currently employs 30 cardiologists, 10 cardiac surgeons and many research scientists. Every year, close to 13,000 procedures are performed on more than 10,000 patients at the hospital.

About Servier Canada

Servier Canada Inc. (www.servier.ca) is a pharmaceutical company based in Laval, Quebec, and in Mississauga, Ontario. Present in Quebec since 1978, the company focuses on the development of therapies to treat cardiovascular, metabolic and central nervous system diseases.

Servier Canada Inc. is the Canadian subsidiary of the Servier Research Group, the leading French-based independent pharmaceutical company, which is present in 140 countries around the world.

- 30 -

For additional information, please contact:

Sylvianne Gervoise
Director, Public Affairs
Institut de cardiologie de Québec
418-656-4564
sylvianne.gervoise@crhl.ulaval.ca

Sylvie Patry
Consultant
NATIONAL Public Relations
418-648-1233
spatry@national.ca